University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Daphne A. Haas-Kogan

Daphne A. Haas-Kogan, M.D.

Radiation cancer specialist

Dr. Daphne A. Haas-Kogan is a radiation oncologist and expert in the treatment of cancers in adults and children. In addition to caring for patients, she investigates the effects of radiation therapy and gene therapy on cancer tumors, in particular an often fatal brain tumor called glioblastoma multiforme. Her research has been published widely in medical and science journals.

Haas-Kogan earned a medical degree and completed a residency in radiation oncology at the University of California, San Francisco, where she served as chief resident in radiation oncology. She is the recipient of numerous awards for research and teaching. She is a professor of radiation oncology and neurological surgery and is vice chair of the Department of Radiation Oncology at UCSF.

Conditions & Treatments

Clinics

Neuro-Oncology Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2966
Fax: (415) 353-2167

Hours: Monday to Friday
8 a.m. – 5 p.m.

Radiation Oncology at Mount Zion
1600 Divisadero St., Basement Level
San Francisco, CA 94143-1708
Phone: (415) 353-9807
Fax: (415) 353-9884

Hours: Monday to Friday
7 a.m. – 6 p.m.

Radiation Oncology at Parnassus
505 Parnassus Ave, Room L-75
San Francisco, CA 94143-0226
Phone: (415) 353-8335
Fax: (415) 353-7281

Hours: Monday to Friday
8 a.m. – 4:30 p.m.

More about Daphne A. Haas-Kogan

Additional Languages

Hebrew

Education

UCSF Medical Center 1991

Residencies

UCSF Medical Center, Radiation Oncology 1997

Selected Research and Publications

  1. Schoenfeld A, Pekmezci M, Barnes MJ, Tihan T, Gupta N, Lamborn KR, Banerjee A, Mueller S, Chang S, Berger MS, Haas-Kogan D. The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. J Neurooncol. 2012 May; 108(1):133-9.
  2. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):315-25.
  3. Pejavar S, Polley MY, Rosenberg-Wohl S, Chennupati S, Prados MD, Berger MS, Banerjee A, Gupta N, Haas-Kogan D. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012 Jan; 106(2):367-75.
  4. Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28; 306(2):223-9.
  5. More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, Vanbrocklin HF, Weiss WA, Mueller S, Haas-Kogan DA, Dubois SG, Matthay KK, Giacomini KM. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011 Apr 15; 17(8):2339-49.
  6. Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011 Sep 15; 117(18):4286-93.
  7. Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C, Haas-Kogan DA, McBride S, Marsit CJ, Christensen BC, Nelson HH, Stokoe D, Wiemels JL, Chang SM, Prados MD, Tihan T, Vandenberg SR, Kelsey KT, Berger MS, Wiencke JK. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol. 2011 Mar; 13(3):280-9.
  8. Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, Packer RJ, Boyett JM, Kun LE. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011 Mar; 13(3):298-306.
  9. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011 Apr; 13(4):384-92.
  10. Poussaint TY, Kocak M, Vajapeyam S, Packer RI, Robertson RL, Geyer R, Haas-Kogan D, Pollack IF, Vezina G, Zimmerman R, Cha S, Patay Z, Boyett JM, Kun LE. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol. 2011 Apr; 13(4):417-27.
  11. Zukotynski KA, Fahey FH, Kocak M, Alavi A, Wong TZ, Treves ST, Shulkin BL, Haas-Kogan DA, Geyer JR, Vajapeyam S, Boyett JM, Kun LE, Poussaint TY. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2011 Feb; 52(2):188-95.
  12. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal. 2010; 3(147):ra81.
  13. Prabhu SP, Ng S, Vajapeyam S, Kieran MW, Pollack IF, Geyer R, Haas-Kogan D, Boyett JM, Kun L, Poussaint TY. DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium. Childs Nerv Syst. 2011 Jan; 27(1):11-8.
  14. Chen CP, Haas-Kogan D. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Rev Mol Diagn. 2010 Oct; 10(7):883-95.
  15. Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010 Sep; 37(9):4861-7.
  16. Mishra KK, Squire S, Lamborn K, Banerjee A, Gupta N, Wara WM, Prados MD, Berger MS, Haas-Kogan DA. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol. 2010 Oct; 100(1):121-7.
  17. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010 Feb 15; 70(4):1296-305.
  18. Prasad G, Haas-Kogan DA. Radiation-induced gliomas. Expert Rev Neurother. 2009 Oct; 9(10):1511-7.
  19. Sutton EJ, Tong RT, Gillis AM, Henning TD, Weinberg VA, Boddington S, Haas-Kogan DA, Matthay K, Sha V, Gooding C, Coakley FV, Daldrup-Link H. Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy. Pediatr Radiol. 2009 Nov; 39(11):1194-202.
  20. McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010 Mar; 97(1):33-40.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California